Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients

Is the apolipoprotein E mimetic peptide CN-105 safe and feasible for reducing postoperative delirium in older surgical patients?In this phase 2 randomized clinical trial involving 186 patients, those who received intravenous CN-105 (vs placebo) experienced fewer grade 2 or higher postoperative adverse events, and more than 90% of CN-105 doses were administered within the appropriate time window. The postoperative delirium rates in the CN-105 and placebo groups were 19.3% vs 26.5%, respectively.The findings suggest that CN-105 was feasible to administer and did not lead to any meaningful safety issues; a phase 3 trial is warranted to study the efficacy of CN-105 for reducing postoperative adverse events and to more precisely determine its effects on postoperative delirium.

Corresponding Author: Miles Berger, MD, PhD, Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, 300 Pasteur Dr, Room H3580, MC 5640, Stanford CA 94305 (mberger1@stanford.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.